| Literature DB >> 32415816 |
Semir Bešlija1, Zdenka Gojković2, Timur Cerić1, Alma Mekić Abazović3, Inga Marijanović4, Semir Vranić5, Jasminka Mustedanagić-Mujanović6, Faruk Skenderi1, Ivanka Rakita2, Aleksandar Guzijan2, Dijana Koprić6, Alen Humačkić7, Danijela Trokić8, Jasmina Alidžanović6, Alma Efendić3, Ibrahim Šišić3, Harun Drljević3, Vanesa Bešlagić1, Božana Babić2, Azra Pašić3, Anela Ramić3, Dijana Mikić2, Zlatko Guzin7, Dragana Karan4, Teo Buhovac4, Dragana Miletić4, Senad Šečić1, Azra Đozić Šahmić1, Lejla Mujbegović3, Alisa Kubura3, Mensura Burina6, Nenad Lalović9, Nikolina Dukić9, Jelena Vladičić Mašić9, Mirjana Ćuk9, Rajna Stanušić9.
Abstract
The HERe2Cure project, which involved a group of breast cancer experts, members of multidisciplinary tumor boards from healthcare institutions in Bosnia and Herzegovina, was initiated with the aim of defining an optimal approach to the diagnosis and treatment of HER2 positive breast cancer. After individual multidisciplinary consensus meetings were held in all oncology centers in Bosnia and Herzegovina, a final consensus meeting was held in order to reconcile the final conclusions discussed in individual meetings. Guidelines were adopted by consensus, based on the presentations and suggestions of experts, which were first discussed in a panel discussion and then agreed electronically between all the authors mentioned. The conclusions of the panel discussion represent the consensus of experts in the field of breast cancer diagnosis and treatment in Bosnia and Herzegovina. The objectives of the guidelines include the standardization, harmonization and optimization of the procedures for the diagnosis, treatment and monitoring of patients with HER2-positive breast cancer, all of which should lead to an improvement in the quality of health care of mentioned patients. The initial treatment plan for patients with HER2-positive breast cancer must be made by a multidisciplinary tumor board comprised of at least: a medical oncologist, a pathologist, a radiologist, a surgeon, and a radiation oncologist/radiotherapist.Entities:
Year: 2021 PMID: 32415816 PMCID: PMC7982071 DOI: 10.17305/bjbms.2020.4846
Source DB: PubMed Journal: Bosn J Basic Med Sci ISSN: 1512-8601 Impact factor: 3.363